Secondary analysis of the phase III ARASENS trial (n=1305, metastatic hormone-sensitive prostate cancer): darolutamide plus ADT and docetaxel vs placebo delayed mCRPC (HR 0.36) and pain progression (HR 0.79); pain interference/severity and HRQoL worsening were similar.
Secondary analysisn = 1,305
Fizazi et al. Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial